FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp)

View source ↗

Summary

The FDA approved a supplemental application for ibandronate sodium from Apotex Corp, typically indicating a labeling modification under the ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Paget Disease of Bone

Drugs mentioned

• IBANDRONATE SODIUM (ibandronate sodium)

Snippet

SUPPL AP for IBANDRONATE SODIUM (IBANDRONATE SODIUM)